不安障害 (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "不安障害" in Japanese language version.

refsWebsite

Global rank Japanese rank

27nih.gov

4^th place

24^th place

17doi.org

2^nd place

6^th place

7google.co.jp

934^th place

57^th place

3nice.org.uk

3,258^th place

1,755^th place

2sciencedirect.com

149^th place

558^th place

2handle.net

102^nd place

78^th place

2ama-assn.org

3,257^th place

6,629^th place

1psychiatryonline.org

4,032^nd place

6,830^th place

1google.co.uk

504^th place

945^th place

1psychosomaticmedicine.org

low place

1web.archive.org

1^st place

1psychology.org.nz

low place

1jamanetwork.com

2,650^th place

3,384^th place

1nature.com

234^th place

363^rd place

1harvard.edu

18^th place

107^th place

1webcitation.org

24^th place

152^nd place

1jhu.edu

699^th place

4,621^st place

ama-assn.org

archpsyc.ama-assn.org

Jonathan R. T. Davidson, MD; Edna B. Foa, PhD; et al. Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placebo in Generalized Social Phobia 1998. Retrieved March 1, 2006.

archinte.ama-assn.org

Herring P, O’Connor P, Dishman R (2010-02-22). “The Effect of Exercise Training on Anxiety Symptoms Among Patients”. Archives of Internal Medicine (American Medical Association) 170 (4): 321–331. doi:10.1001/archinternmed.2009.530. PMID 20177034. オリジナルの2010年6月23日時点におけるアーカイブ。 2010年6月14日閲覧。.

doi.org

Zung WW (1971). “A rating instrument for anxiety disorders”. Psychosomatics 12 (6): 371–379. doi:10.1016/S0033-3182(71)71479-0. PMID 5172928.
Enna SJ (1984). “Role of gamma-aminobutyric acid in anxiety”. Psychopathology 17 (Suppl 1): 15–24. doi:10.1159/000284073. PMID 6143341.
Dunlop BW, Davis PG (2008). “Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review”. Prim Care Companion J Clin Psychiatry 10 (3): 222–228. doi:10.4088/PCC.v10n0307. PMC 2446479. PMID 18615162.
Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews PM, Cowen PJ (2004). “Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor”. Am J Psychiatry 161 (2): 368–370. doi:10.1176/appi.ajp.161.2.368. PMID 14754790.
Winston AP (2005). “Neuropsychiatric effects of caffeine”. Advances in Psychiatric Treatment 11 (6): 432–439. doi:10.1192/apt.11.6.432.
Hughes RN (June 1996). “Drugs Which Induce Anxiety: Caffeine”. New Zealand Journal of Psychology 25 (1): 36–42. doi:10.1016/S0278-6915(02)00096-0. PMID 12204388. オリジナルの2013年2月9日時点におけるアーカイブ。.
Vilarim MM, Rocha Araujo DM, Nardi AE (August 2011). “Caffeine challenge test and panic disorder: a systematic literature review”. Expert Rev Neurother 11 (8): 1185–95. doi:10.1586/ern.11.83. PMID 21797659.
Vilarim, Marina Machado; Rocha Araujo, Daniele Marano; Nardi, Antonio Egidio (2011). “Caffeine challenge test and panic disorder: A systematic literature review”. Expert Review of Neurotherapeutics 11 (8): 1185–95. doi:10.1586/ern.11.83. PMID 21797659.
Lee, Myung Ae; Cameron, Oliver G.; Greden, John F. (1985). “Anxiety and caffeine consumption in people with anxiety disorders”. Psychiatry Research 15 (3): 211–7. doi:10.1016/0165-1781(85)90078-2. PMID 3862156.
Bruce, Malcolm; Scott, N; Shine, P; Lader, M (1992). “Anxiogenic Effects of Caffeine in Patients with Anxiety Disorders”. Archives of General Psychiatry 49 (11): 867–9. doi:10.1001/archpsyc.1992.01820110031004. PMID 1444724.
Nardi, Antonio E.; Lopes, Fabiana L.; Valença, Alexandre M.; Freire, Rafael C.; Veras, André B.; De-Melo-Neto, Valfrido L.; Nascimento, Isabella; King, Anna Lucia et al. (2007). “Caffeine challenge test in panic disorder and depression with panic attacks”. Comprehensive Psychiatry 48 (3): 257–63. doi:10.1016/j.comppsych.2006.12.001. PMID 17445520.
Nutt, David J; Rogers, Peter J; Hohoff, Christa; Heatherley, Susan V; Mullings, Emma L; Maxfield, Peter J; Evershed, Richard P; Deckert, Jürgen (August 2010). “Association of the Anxiogenic and Alerting Effects of Caffeine with ADORA2A and ADORA1 Polymorphisms and Habitual Level of Caffeine Consumption”. Neuropsychopharmacology 35 (9): 1973–1983. doi:10.1038/npp.2010.71. PMC 3055635. PMID 20520601.
Bruce, M. S.; Lader, M. (February 2009). “Caffeine abstention in the management of anxiety disorders”. Psychological Medicine 19 (01): 211. doi:10.1017/S003329170001117X. PMID 2727208.
Juliano LM, Griffiths RR (2004). “A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features”. Psychopharmacology (Berl.) 176 (1): 1–29. doi:10.1007/s00213-004-2000-x. PMID 15448977. オリジナルの2012年1月29日時点におけるアーカイブ。.
Herring P, O’Connor P, Dishman R (2010-02-22). “The Effect of Exercise Training on Anxiety Symptoms Among Patients”. Archives of Internal Medicine (American Medical Association) 170 (4): 321–331. doi:10.1001/archinternmed.2009.530. PMID 20177034. オリジナルの2010年6月23日時点におけるアーカイブ。 2010年6月14日閲覧。.
Lee YL, Wu Y, Tsang HW, Leung AY, Cheung WM (February 2011). “A systematic review on the anxiolytic effects of aromatherapy in people with anxiety symptoms”. J Altern Complement Med (2): 101–8. doi:10.1089/acm.2009.0277. PMID 21309711.
Vos, T; Flaxman, AD; Naghavi, M; Lozano, R; Michaud, C; Ezzati, M; Shibuya, K; Salomon, JA et al. (2012-12-15). “Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010”. Lancet 380 (9859): 2163–96. doi:10.1016/S0140-6736(12)61729-2. PMID 23245607.

google.co.jp

books.google.co.jp

google.co.uk

books.google.co.uk

Johnson, Bankole A. (2011). Addiction medicine : science and practic. New York: Springer. pp. 301–303. ISBN 978-1-4419-0337-2

handle.net

hdl.handle.net

堀口美智子 (2008). 子供の不安症、抑うつの予防介入プログラム : "FRIENDS"導入の可能性の検討. 格差センシティブな人間発達科学の創成, 3, 47-55.
伊藤拓、及川恵、西河正行 (2013). 英国, 米国の学生相談機関による集団形式のプログラムの展望－日本における精神的不適応予防のための集団形式のプログラム実施のポイントの検討－. 明治学院大学心理学紀要, 23, 123-136, hdl:10723/1742

harvard.edu

health.harvard.edu

“Take note of worrying”. Harvard Health Publishing (2015年6月). 2020年2月18日閲覧。

jamanetwork.com

archpsyc.jamanetwork.com

Bruce, Malcolm; Scott, N; Shine, P; Lader, M (1992). “Anxiogenic Effects of Caffeine in Patients with Anxiety Disorders”. Archives of General Psychiatry 49 (11): 867–9. doi:10.1001/archpsyc.1992.01820110031004. PMID 1444724.

jhu.edu

neuroscience.jhu.edu

Juliano LM, Griffiths RR (2004). “A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features”. Psychopharmacology (Berl.) 176 (1): 1–29. doi:10.1007/s00213-004-2000-x. PMID 15448977. オリジナルの2012年1月29日時点におけるアーカイブ。.

nature.com

Nutt, David J; Rogers, Peter J; Hohoff, Christa; Heatherley, Susan V; Mullings, Emma L; Maxfield, Peter J; Evershed, Richard P; Deckert, Jürgen (August 2010). “Association of the Anxiogenic and Alerting Effects of Caffeine with ADORA2A and ADORA1 Polymorphisms and Habitual Level of Caffeine Consumption”. Neuropsychopharmacology 35 (9): 1973–1983. doi:10.1038/npp.2010.71. PMC 3055635. PMID 20520601.

nice.org.uk

英国国立医療技術評価機構 2014, Quality statement 2. QS53 - Anxiety disorders (Report). 英国国立医療技術評価機構. 2014年2月.
CG113 - Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community care (Report). 英国国立医療技術評価機構. 2011年1月. Guidance chapt.1.2.23.
英国国立医療技術評価機構 2014, Quality statement 3. QS53 - Anxiety disorders (Report). 英国国立医療技術評価機構. 2014年2月.

nih.gov

pubmed.ncbi.nlm.nih.gov

Zung WW (1971). “A rating instrument for anxiety disorders”. Psychosomatics 12 (6): 371–379. doi:10.1016/S0033-3182(71)71479-0. PMID 5172928.
Lydiard RB (2003). “The role of GABA in anxiety disorders”. J Clin Psychiatry 64 (Suppl 3): 21–27. PMID 12662130.
Nemeroff CB (2003). “The role of GABA in the pathophysiology and treatment of anxiety disorders”. Psychopharmacol Bull 37 (4): 133–146. PMID 15131523.
Enna SJ (1984). “Role of gamma-aminobutyric acid in anxiety”. Psychopathology 17 (Suppl 1): 15–24. doi:10.1159/000284073. PMID 6143341.
Dunlop BW, Davis PG (2008). “Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review”. Prim Care Companion J Clin Psychiatry 10 (3): 222–228. doi:10.4088/PCC.v10n0307. PMC 2446479. PMID 18615162.
Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews PM, Cowen PJ (2004). “Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor”. Am J Psychiatry 161 (2): 368–370. doi:10.1176/appi.ajp.161.2.368. PMID 14754790.
Cohen SI (February 1995). “Alcohol and benzodiazepines generate anxiety, panic and phobias”. J R Soc Med 88 (2): 73–77. PMC 1295099. PMID 7769598.
Morrow LA et al. (2000). “Increased incidence of anxiety and depressive disorders in persons with organic solvent exposure”. Psychosomat Med 62 (6): 746–750. PMID 11138992.
Hughes RN (June 1996). “Drugs Which Induce Anxiety: Caffeine”. New Zealand Journal of Psychology 25 (1): 36–42. doi:10.1016/S0278-6915(02)00096-0. PMID 12204388. オリジナルの2013年2月9日時点におけるアーカイブ。.
Vilarim MM, Rocha Araujo DM, Nardi AE (August 2011). “Caffeine challenge test and panic disorder: a systematic literature review”. Expert Rev Neurother 11 (8): 1185–95. doi:10.1586/ern.11.83. PMID 21797659.
Vilarim, Marina Machado; Rocha Araujo, Daniele Marano; Nardi, Antonio Egidio (2011). “Caffeine challenge test and panic disorder: A systematic literature review”. Expert Review of Neurotherapeutics 11 (8): 1185–95. doi:10.1586/ern.11.83. PMID 21797659.
Lee, Myung Ae; Cameron, Oliver G.; Greden, John F. (1985). “Anxiety and caffeine consumption in people with anxiety disorders”. Psychiatry Research 15 (3): 211–7. doi:10.1016/0165-1781(85)90078-2. PMID 3862156.
Lee MA, Flegel P, Greden JF, Cameron OG (May 1988). “Anxiogenic effects of caffeine on panic and depressed patients”. The American Journal of Psychiatry 145 (5): 632–5. PMID 3358468.
Bruce, Malcolm; Scott, N; Shine, P; Lader, M (1992). “Anxiogenic Effects of Caffeine in Patients with Anxiety Disorders”. Archives of General Psychiatry 49 (11): 867–9. doi:10.1001/archpsyc.1992.01820110031004. PMID 1444724.
Nardi, Antonio E.; Lopes, Fabiana L.; Valença, Alexandre M.; Freire, Rafael C.; Veras, André B.; De-Melo-Neto, Valfrido L.; Nascimento, Isabella; King, Anna Lucia et al. (2007). “Caffeine challenge test in panic disorder and depression with panic attacks”. Comprehensive Psychiatry 48 (3): 257–63. doi:10.1016/j.comppsych.2006.12.001. PMID 17445520.
Nutt, David J; Rogers, Peter J; Hohoff, Christa; Heatherley, Susan V; Mullings, Emma L; Maxfield, Peter J; Evershed, Richard P; Deckert, Jürgen (August 2010). “Association of the Anxiogenic and Alerting Effects of Caffeine with ADORA2A and ADORA1 Polymorphisms and Habitual Level of Caffeine Consumption”. Neuropsychopharmacology 35 (9): 1973–1983. doi:10.1038/npp.2010.71. PMC 3055635. PMID 20520601.
Bruce, M. S.; Lader, M. (February 2009). “Caffeine abstention in the management of anxiety disorders”. Psychological Medicine 19 (01): 211. doi:10.1017/S003329170001117X. PMID 2727208.
Juliano LM, Griffiths RR (2004). “A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features”. Psychopharmacology (Berl.) 176 (1): 1–29. doi:10.1007/s00213-004-2000-x. PMID 15448977. オリジナルの2012年1月29日時点におけるアーカイブ。.
Herring P, O’Connor P, Dishman R (2010-02-22). “The Effect of Exercise Training on Anxiety Symptoms Among Patients”. Archives of Internal Medicine (American Medical Association) 170 (4): 321–331. doi:10.1001/archinternmed.2009.530. PMID 20177034. オリジナルの2010年6月23日時点におけるアーカイブ。 2010年6月14日閲覧。.
Li, AW; Goldsmith, CA (2012 Mar). “The effects of yoga on anxiety and stress”. Alternative medicine review : a journal of clinical therapeutic 17 (1): 21–35. PMID 22502620.
Lee YL, Wu Y, Tsang HW, Leung AY, Cheung WM (February 2011). “A systematic review on the anxiolytic effects of aromatherapy in people with anxiety symptoms”. J Altern Complement Med (2): 101–8. doi:10.1089/acm.2009.0277. PMID 21309711.
Vos, T; Flaxman, AD; Naghavi, M; Lozano, R; Michaud, C; Ezzati, M; Shibuya, K; Salomon, JA et al. (2012-12-15). “Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010”. Lancet 380 (9859): 2163–96. doi:10.1016/S0140-6736(12)61729-2. PMID 23245607.

pmc.ncbi.nlm.nih.gov

Dunlop BW, Davis PG (2008). “Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review”. Prim Care Companion J Clin Psychiatry 10 (3): 222–228. doi:10.4088/PCC.v10n0307. PMC 2446479. PMID 18615162.
Cohen SI (February 1995). “Alcohol and benzodiazepines generate anxiety, panic and phobias”. J R Soc Med 88 (2): 73–77. PMC 1295099. PMID 7769598.
Nutt, David J; Rogers, Peter J; Hohoff, Christa; Heatherley, Susan V; Mullings, Emma L; Maxfield, Peter J; Evershed, Richard P; Deckert, Jürgen (August 2010). “Association of the Anxiogenic and Alerting Effects of Caffeine with ADORA2A and ADORA1 Polymorphisms and Habitual Level of Caffeine Consumption”. Neuropsychopharmacology 35 (9): 1973–1983. doi:10.1038/npp.2010.71. PMC 3055635. PMID 20520601.

ncbi.nlm.nih.gov

psychiatryonline.org

ajp.psychiatryonline.org

Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews PM, Cowen PJ (2004). “Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor”. Am J Psychiatry 161 (2): 368–370. doi:10.1176/appi.ajp.161.2.368. PMID 14754790.

psychology.org.nz

Hughes RN (June 1996). “Drugs Which Induce Anxiety: Caffeine”. New Zealand Journal of Psychology 25 (1): 36–42. doi:10.1016/S0278-6915(02)00096-0. PMID 12204388. オリジナルの2013年2月9日時点におけるアーカイブ。.

psychosomaticmedicine.org

Morrow LA et al. (2000). “Increased incidence of anxiety and depressive disorders in persons with organic solvent exposure”. Psychosomat Med 62 (6): 746–750. PMID 11138992.

sciencedirect.com

Lee, Myung Ae; Cameron, Oliver G.; Greden, John F. (1985). “Anxiety and caffeine consumption in people with anxiety disorders”. Psychiatry Research 15 (3): 211–7. doi:10.1016/0165-1781(85)90078-2. PMID 3862156.
Werner-Seidler, A., Perry, Y., Calear, A. L., Newby, J. M., Christensen, H. (2017). School-based depression and anxiety prevention programs for young people: A systematic review and meta-analysis. Clinical Psychology Review, 51, 30-47.

web.archive.org

Hughes RN (June 1996). “Drugs Which Induce Anxiety: Caffeine”. New Zealand Journal of Psychology 25 (1): 36–42. doi:10.1016/S0278-6915(02)00096-0. PMID 12204388. オリジナルの2013年2月9日時点におけるアーカイブ。.

webcitation.org

Juliano LM, Griffiths RR (2004). “A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features”. Psychopharmacology (Berl.) 176 (1): 1–29. doi:10.1007/s00213-004-2000-x. PMID 15448977. オリジナルの2012年1月29日時点におけるアーカイブ。.